Pharma major Venus Remedies today said it will commercially launch its new drug, 'Trois', for treatment of arthritis in June or July to tackle what is predicted to become the "biggest epidemic" in India by 2013 with a $672 million market for rheumatoid arthritis drugs.
It also said that it was carrying out research on developing innovative drugs for treating viral diseases and immune system enhancing medicines.
"We will launch 'Trois' in the month of June or July," the company's Joint Managing Director-cum-Director Research Manu Chaudhary said today.
"This nano technology-based product, Trois, has many advantages, as it has got 178% faster penetration that leads to quick onset of action resulting in enhanced bioavailability, reduction in pain and inflammation associated with arthritis," Chaudhary said.
This technology is fully developed and the patent for this technology has already been filed and grants are expected soon, she said.
According to a survey, nearly 70% of people above 65 years of age are suffering from arthritis in India and it would become the biggest epidemic of the country by 2013.
The rheumatoid arthritis drug market in India will be more than double by 2013, growing from $296 million in 2008 to $672 million in 2013.
About 1% of the world's population has rheumatoid arthritis. Its market is expected to exceed $23.12 billion by 2015.
Arthritis is one of the most chronic health problems in the world and one of the USA's most common causes of disability. An estimated 46 million adults in the United States that have arthritis and related conditions could benefit from 'Trois'.
The Panchkula-based company has also been awarded a Gold Medal under DST-Lockheed Martin India's Innovation Growth Program-2011 for integrated medicinal research product 'Trois'.
